Combined mpMRI/US fusion targeted and concurrent standard biopsies in the detection of prostate cancer: a retrospective study.
Prostate cancer
mpMRI/US fusion targeted biopsy
standard US-guided systematic biopsy
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
03
2021
accepted:
10
05
2021
entrez:
17
11
2021
pubmed:
18
11
2021
medline:
18
11
2021
Statut:
epublish
Résumé
In this retrospective study we compared the PCa detection rates between combined (combined MRI/US fusion targeted biopsy with concurrent standard biopsy) and standard systemic, combined and targeted (component), and targeted (component) and concurrent standard (component) biopsies. Two cohorts, totaling 735 cases, were selected from the University of Wisconsin Pathology archive. 390 cases (cohort 1) were combined biopsies from 2017-2020 and 345 cases (cohort 2) were part of the standard US-guided systematic biopsies from the same period. PCa was stratified into three categories: low, intermediate, and high risks. We found that combined biopsy was significantly better than the standard biopsy in detection of PCa (65.4% vs. 51.6%, P<0.01) and intermediate-risk PCa (18.7% vs. 10.4%, P=0.05) but only slightly better at detecting high-risk PCa (26.7% vs. 23.5%, P=0.32). Further examining the biopsy results in cohort 1, we found that combined biopsy was superior to targeted biopsy (65.4% vs. 56.9%, P=0.02) or concurrent standard biopsy (65.4% vs. 52.1%, P=0.0002) in PCa detection. Combined biopsy detected significantly more high-risk PCa than concurrent standard biopsy (26.7% vs. 17.4, P=0.002), but the difference in detecting high-risk PCa between combined and targeted biopsies was not significant (26.7% vs. 22.1%, P=0.133). Similarly, the differences in detecting PCa and high-risk PCa between targeted and concurrent standard biopsies were not significant (56.9% vs. 52.1%, P=0.172 and 22.1% vs. 17.4, P=0.133, respectively). Both targeted and concurrent standard biopsies missed PCa of each risk level. Combined MRI/US fusion targeted plus standard prostate biopsy is a superior technique for the detection of PCa and clinically significant PCa.
Types de publication
Journal Article
Langues
eng
Pagination
12107-12113Informations de copyright
AJTR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
BJU Int. 2018 Jul;122(1):50-58
pubmed: 29388388
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Eur Urol. 2015 Dec;68(6):1045-53
pubmed: 25656808
Curr Opin Urol. 2013 Jan;23(1):43-50
pubmed: 23138468
J Urol. 2013 Nov;190(5):1721-1727
pubmed: 23727310
Eur Urol. 2013 Nov;64(5):713-719
pubmed: 23787357
Clin Oncol (R Coll Radiol). 2020 Mar;32(3):144-148
pubmed: 31864796
Curr Opin Urol. 2008 Jan;18(1):71-7
pubmed: 18090494
Urology. 2011 Dec;78(6):1356-62
pubmed: 21840577
Urol Oncol. 2014 Aug;32(6):903-11
pubmed: 24239473
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Eur Urol. 2014 Sep;66(3):430-6
pubmed: 24377803
Urology. 2017 Dec;110:154-160
pubmed: 28866023
J Urol. 2011 Oct;186(4):1281-5
pubmed: 21849184
Eur Radiol. 2012 Apr;22(4):746-57
pubmed: 22322308
BJU Int. 2020 Nov;126(5):568-576
pubmed: 32438463
Health Technol Assess. 2018 Jul;22(39):1-176
pubmed: 30040065
J Urol. 2014 Jun;191(6):1749-54
pubmed: 24333515
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):71-7
pubmed: 19786982
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
J Urol. 2012 Dec;188(6):2152-2157
pubmed: 23083875
Urol Oncol. 2016 Mar;34(3):119.e1-9
pubmed: 26602178
Eur Urol. 2018 Jan;73(1):23-30
pubmed: 28935163
Eur Urol. 2015 Jun;67(6):1112-1121
pubmed: 25466942
J Urol. 2013 Oct;190(4):1380-6
pubmed: 23608676